Lilly Plans $3 Billion Expansion of US Facility in Wisconsin
US drug manufacturer Eli Lilly announced a $3 billion expansion of its US manufacturing facility in Kenosha County, Wisconsin, that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network for diabetes, obesity and future medicines across therapeutic areas.
Construction work on the expansion is set to begin next year and Lilly expects the expansion to add 750 jobs to the current workforce of more than 100 at this location.
"Today's announcement represents our single largest US manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest," said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations.
The acquisition, expansion and additional purchases of land and the adjacent warehouse will raise Lilly's total planned investment in Wisconsin to $4 billion, the company said. The expanded facility will focus on manufacturing injectable medicines, device assembly and packaging for medicines across multiple therapeutic areas.
